Imiquimod
- Generic Name
- Imiquimod
- Brand Names
- Aldara, Vyloma, Zyclara
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N4
- CAS Number
- 99011-02-6
- Unique Ingredient Identifier
- P1QW714R7M
- Background
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...
- Indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
- Associated Conditions
- Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
- Associated Therapies
- -
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2023-08-31
- Target Recruit Count
- 75
- Registration Number
- NCT00788164
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 258
- Registration Number
- NCT00777127
- Locations
- 🇫🇷
Hospital Sainte Marguerite, Department for Dermatology and Venereology, Pavilion 3, First Floor, Marseille, France
🇫🇷CHU St Jacques, Department for Dermatology, Besancon Cedex, France
🇩🇪Derma Center Vechta, Vechta, Germany
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
- Conditions
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Target Recruit Count
- 470
- Registration Number
- NCT00674739
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center Dermatology Dept, Dallas, Texas, United States
🇺🇸Dermatology Practice, Ann Arbor, Michigan, United States
🇺🇸Alegent Health Clinic, Omaha, Nebraska, United States
Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 27
- Registration Number
- NCT00585247
- Locations
- 🇺🇸
Beckman Laser Institute Medical and Surgical Cilnic, Irvine, California, United States
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00504023
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 9
- Registration Number
- NCT00470392
- Locations
- 🇺🇸
VA Medical Center, Cleveland, Cleveland, Ohio, United States
🇺🇸University Hospital Case Medical Center, Cleveland, Ohio, United States
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
- Conditions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 11
- Registration Number
- NCT00453050
- Locations
- 🇺🇸
Oklahoma University Cancer Institute, Tulsa, Oklahoma, United States
Topical Imiquimod for Bowen's Disease of the Head and Neck
- Conditions
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2008-03-26
- Lead Sponsor
- Brooke Army Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00384124
- Locations
- 🇺🇸
Brooke Army Medical Center Department of Dermatology, Fort Sam Houston, Texas, United States
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
- Conditions
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 15
- Registration Number
- NCT00314756
- Locations
- 🇺🇸
Wake Forest University Medical Center, Winston-Salem, North Carolina, United States
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 104
- Registration Number
- NCT00273910
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.